新冠病毒疫苗接种可能诱发可逆性脑血管收缩综合征发作：一例报告

Lund Anne Marie, Al-Karagholi Mohammad Al-Mahdi

Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.

Department of Neurology, Rigshospitalet Glostrup, 2600 Glostrup, Denmark.

Vaccines (Basel). 2022 May 23;10(5):823. doi: 10.3390/vaccines10050823.

A 30-year-old male diagnosed three years previously with reversible cerebral vasoconstriction syndrome (RCVS) presented to the department of neurology with an accumulation of attacks mimicking previous RCVS attacks and fulfilling the diagnostic criteria for RCVS after receiving the first Pfizer COVID-19 vaccine. The neurologic exam, blood samples, electrocardiogram (ECG), and computer tomography of the head (CTC) were normal. The patient was treated with the angiotensin 2 receptor antagonist, losartan, with a good response and was discharged with a prescription for losartan lasting until three days after the second Pfizer COVID-19 vaccine. No further RCVS attacks were reported. These findings indicate that the COVID-19 vaccine might induce RCVS attacks in susceptible individuals, and targeting the angiotensin 2 receptor could be a preventive option.

一名三年前被诊断为可逆性脑血管收缩综合征（RCVS）的30岁男性，在接种第一剂辉瑞新冠疫苗后，因出现类似先前RCVS发作的症状且符合RCVS诊断标准，前往神经内科就诊。神经系统检查、血液样本、心电图（ECG）和头部计算机断层扫描（CTC）均正常。患者接受了血管紧张素2受体拮抗剂氯沙坦治疗，反应良好，出院时开具了持续至接种第二剂辉瑞新冠疫苗后三天的氯沙坦处方。未再报告RCVS发作。这些发现表明，新冠疫苗可能会在易感个体中诱发RCVS发作，而针对血管紧张素2受体可能是一种预防选择。